Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage. The company has a collaboration with Hongene Biotech for the manufacturing of RNA and oligonucleotides. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Metrics to compare | APTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.9x | −3.1x | −0.4x | |
PEG Ratio | −0.04 | −0.07 | 0.00 | |
Price/Book | 0.3x | 3.2x | 2.6x | |
Price / LTM Sales | 7.3x | 14.4x | 3.1x | |
Upside (Analyst Target) | - | 121.5% | 57.3% | |
Fair Value Upside | Unlock | 30.0% | 8.0% | Unlock |